STOCK TITAN

Polypid Ltd - PYPD STOCK NEWS

Welcome to our dedicated news page for Polypid (Ticker: PYPD), a resource for investors and traders seeking the latest updates and insights on Polypid.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Polypid's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Polypid's position in the market.

Rhea-AI Summary
PolyPid Ltd. (PYPD) updates on SHIELD II Phase 3 trial for D-PLEX100, reports positive preclinical data, successful financing, and strong financial results. The company aims to improve surgical outcomes and expects top-line results in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.21%
Tags
earnings
-
Rhea-AI Summary
PolyPid Ltd. (Nasdaq: PYPD) announces enrollment of 100th patient in SHIELD II Phase 3 trial for D-PLEX100, with approximately 40 centers open. Unblinded interim analysis expected after 400 patients complete follow-up in mid-2024. Recent $16 million financing extends cash runway through late Q3 2024, with potential additional $19 million if warrants are exercised for NDA submission.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
clinical trial
-
Rhea-AI Summary
PolyPid Ltd. (Nasdaq: PYPD) will report its fourth quarter and full-year 2023 financial results and operational highlights on February 14, 2024. The Company aims to improve surgical outcomes and will host a conference call and webcast to discuss the results and provide an update on business operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
conferences earnings
Rhea-AI Summary
PolyPid Ltd. (Nasdaq: PYPD) announced a private placement financing (the “PIPE”) for $16.2 million in gross proceeds. The financing is led by leading U.S. life sciences-focused investors, DAFNA Capital Management and Rosalind Advisors. The investors have agreed to purchase 3,371,312 of the Company’s ordinary shares at a purchase price of $4.81 per share, with additional warrants to purchase up to 3,371,312 ordinary shares at an exercise price of $5.50 per share. The PIPE is expected to close on January 9, 2024, and the net proceeds will be used for the ongoing SHIELD II phase 3 clinical trial for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, working capital, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.36%
Tags
none
-
Rhea-AI Summary
PolyPid Ltd. (Nasdaq: PYPD) provided a corporate update and reported financial results for the three and nine months ended September 30, 2023. The update highlights the progress of the SHIELD II Phase 3 trial for D-PLEX100, successful completion of manufacturing milestones, and financial results. The company expects to have approximately 40 centers open by the end of 2023, with top-line results from the SHIELD II trial expected in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
earnings
-
Rhea-AI Summary
PolyPid Ltd. (Nasdaq: PYPD) announced the appointment of Nurit Tweezer-Zaks, M.D., M.B.A., to its Board of Directors following the retirement of Anat Tsour Segal. Dr. Tweezer-Zaks is a biopharmaceutical industry veteran with extensive executive business development, clinical, and R&D expertise. She is currently the CEO of MediCane Health, a global medical cannabis company, and previously held senior positions at aMOON and Sanofi. Dr. Tweezer-Zaks will bring her vast expertise to help PolyPid approach critical clinical and regulatory milestones, including the potential commercialization of their late-stage product candidate, D-PLEX100, for the prevention of surgical site infections (SSIs).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.89%
Tags
management
Rhea-AI Summary
PolyPid Ltd. (Nasdaq: PYPD) will report its Q3 2023 financial results and operational highlights on November 8, 2023. The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
PolyPid regains compliance with Nasdaq's minimum bid price requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
none
-
Rhea-AI Summary
PolyPid to present SHIELD I Phase 3 clinical data for D-PLEX100 at American College of Surgeons Clinical Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
none
Rhea-AI Summary
PolyPid announces positive preclinical results demonstrating the safety profile of D-PLEX100 and the PLEX technology platform in juvenile animals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
clinical trial
Polypid Ltd

Nasdaq:PYPD

PYPD Rankings

PYPD Stock Data

30.70M
1.54M
11.93%
17.08%
0.11%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Israel
Petah Tikva

About PYPD

polypid®, a specialty pharmaceutical company, develops and manufactures products based on its plex™ technology. so far, 70 patients have been treated in clinical trials with polypid’s anti-infection products demonstrating safety and efficacy. polypid is in the process of submitting its lead product for phase-iii trial in the us and eu. plex™ is able to optimize drugs'​ therapeutic performance and clinical outcomes. plex™-based protected drug reservoir is implanted directly into the body’s target area thus enabling prolonged delivery of drugs, over periods ranging from days to several months. polypid’s pipeline focuses on 3 products: d-plex™ - intended for prevention and treatment of surgical infections caused by bacteria. its effectiveness is currently being tested in patients undergoing open-heart surgery, with a view to preventing infections that may occur following surgery. the product is currently undergoing clinical studies at several medical centers. bonypid®-1000 - designed to e